Hostname: page-component-848d4c4894-cjp7w Total loading time: 0 Render date: 2024-07-03T13:41:55.887Z Has data issue: false hasContentIssue false
  • English
  • Français

Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender

Published online by Cambridge University Press:  16 April 2020

Shigeru Morishita  and
Seizaburo Arita
Shigeru Morishita*
Affiliation:
Department of Psychiatry, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, 701-0192Okayama, Japan
Seizaburo Arita
Affiliation:
Department of Mathematics, Kansai Medical School, Hirakata, Osaka, Japan
*
*Corresponding author. E-mail address: [email protected] (S. Morishita).
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

FluvoxamineParoxetineMilnacipranGenderDepression
Type
Case reports
Information
European Psychiatry , Volume 18 , Issue 8 , December 2003 , pp. 418 - 420
Copyright
Copyright © 2003 European Psychiatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Caplea, ASeachrist, DDaneshrar, HDunphy, GEly, D. Noradrenergic content and turnover rate in kidney and heart shows gender and strain differences. J Appl Physiol 2002;92:567–71.CrossRefGoogle ScholarPubMed
Coppen, AWhybrow, PCNoguera, RMaggs, RPrange, AJ. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972;26:234–41.CrossRefGoogle ScholarPubMed
Halbreich, UVital-Heme, JGoldstein, SZandek, K. Sex differences in biological factors putatively related to depression. J Affect Disord 1984;7:223–33.CrossRefGoogle ScholarPubMed
Kornstein SG, Schatzberg, AFThase, ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157:1445–52.Google Scholar
Morishita, SArita, S. Possible predictors of response to fluvoxamine for depression. Hum Psychopharmacol Clin Exp 2003;18:197–200.CrossRefGoogle ScholarPubMed
Morishita, SArita, S. The clinical use of milnacipran for depression. Eur Psychiatry 2003;18:34–5.CrossRefGoogle ScholarPubMed
Nelson, JCN. Safety and tolerability of the new antidepressants. J Clin Psychiatry 1977;58(Suppl 6):26–31.Google Scholar
Old Age Depression Interest Group. How long should the elderly take antidepressant? Br J Psychiatry 1993;162:175–82.CrossRefGoogle Scholar
Puech, AMontgomery, SAProst, JFProst, JFSolles, ABriley, M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99–108.CrossRefGoogle ScholarPubMed
Yonkers, KABrawman-Minter, O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002;63: 610–5.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.